Literature DB >> 15695117

Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma.

Sarah L Holley1, Christoph Matthias, Volker Jahnke, Anthony A Fryer, Richard C Strange, Paul R Hoban.   

Abstract

We have examined the association of the CCND1 A/G870 polymorphism with susceptibility and outcome in 174 German patients with oral SCC (OSCC). The CCND1 G870 allele frequency was increased in cases (G870=0.65) when compared to controls (n=155, G870=0.54) and the distribution of CCND1 genotypes were significantly different (p=0.014). Using logistic regression, correcting for age, gender and tobacco consumption, an increased frequency of the CCND1 GG870 genotype was observed in the OSCC cases (p=0.025, OR 3.37, 95% CI 1.61-9.80). No significant associations were observed between CCND1 A/G870 and tumour histological factors. Our data suggests that the CCND1 GG870 genotype is associated with increased susceptibility to OSCC. The involvement of cyclin D1 polymorphism in mechanisms of SCC development may differ in the different sub-sites of the head and neck.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695117     DOI: 10.1016/j.oraloncology.2004.08.005

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  14 in total

1.  CCND1 G870A polymorphism and risk for head and neck cancer: a meta-analysis.

Authors:  Chunbo Tang; Zhanwei Wang; Jinhua Yu; Yunong Wu; Zhijun Zhu; Ning Chen
Journal:  Med Oncol       Date:  2010-05-05       Impact factor: 3.064

2.  Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma.

Authors:  Vanita K Gupta; Andrew Feber; Liqiang Xi; Arjun Pennathur; Maoxin Wu; James D Luketich; Tony E Godfrey
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck.

Authors:  Carmen J Marsit; Candice C Black; Marshall R Posner; Karl T Kelsey
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

4.  Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population.

Authors:  Kaur Satinder; Sobti Ranbir Chander; Kaur Pushpinder; Gupta Indu; Jain Veena
Journal:  Mol Cell Biochem       Date:  2008-06-12       Impact factor: 3.396

5.  Cyclin D1 polymorphism and oral cancer: a meta-analysis.

Authors:  Wenjun Wang; Yuming Zhao; Jie Yang; Bichen Lin; Haiyong Gu; Xiaoqing Cao; Lihong Ge
Journal:  Mol Biol Rep       Date:  2012-10-31       Impact factor: 2.316

6.  Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis.

Authors:  Lili Wang; Zhiying Wang; Xiuqiu Gao; Xin Li; Xirao Sun; Changfu Liu
Journal:  Tumour Biol       Date:  2013-11-05

7.  Oral carcinogenesis and oral cancer chemoprevention: a review.

Authors:  Takuji Tanaka; Mayu Tanaka; Takahiro Tanaka
Journal:  Patholog Res Int       Date:  2011-05-22

Review 8.  A review of genetic epidemiology of head and neck cancer related to polymorphisms in metabolic genes, cell cycle control and alcohol metabolism.

Authors:  G Cadoni; S Boccia; L Petrelli; P Di Giannantonio; D Arzani; A Giorgio; E De Feo; M Pandolfini; P Gallì; G Paludetti; G Ricciardi
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-02       Impact factor: 2.124

9.  Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population.

Authors:  Zhenzhen Zeng; Jing Tu; Jin Cheng; Mingjie Yao; Yali Wu; Xiangbo Huang; Xiaomeng Xie; Xiaolei Zhang; Fengmin Lu; Xiangmei Chen
Journal:  Tumour Biol       Date:  2015-04-08

10.  Lack of association of the cyclin D1 G870A variation with oral carcinoma risk: Evidence from 2,404 subjects.

Authors:  Xian-Lu Zhuo; Jun-Jun Ling; Hou-Yu Zhao; Yan Zhou; Yu-Feng Song; Ying-Hui Tan
Journal:  Exp Ther Med       Date:  2012-07-24       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.